HALO vs RPRX
HALO: Halozyme is a biopharmaceutical company that licenses its proprietary drug-delivery technology to help pharmaceutical partners convert intravenous treatments into more convenient subcutaneous injections. RPRX: Royalty Pharma is the leading acquirer of biopharmaceutical royalties, providing capital to the healthcare industry in exchange for long-term rights to drug revenue streams.
Side-by-side fundamentals
| Metric | HALO | RPRX | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $103.12 | $56.77 | |
| Market cap as of 2026-08-10 | $12.2B | $22.0B | |
| P/E as of 2026-08-10 | 29.57 | 40.06 | HALO lower |
| PEG as of 2026-08-10 | 0.94 | 3.59 | HALO lower |
| Net margin as of 2026-08-10 | +24.9% | +32.1% | RPRX higher |
| Gross margin as of 2026-08-10 | +82.4% | n/a | |
| Operating margin as of 2026-08-10 | +35.6% | +59.6% | RPRX higher |
| ROE as of 2026-08-10 | +180.6% | +12.3% | HALO higher |
| ROA as of 2026-08-10 | +16.6% | +4.2% | HALO higher |
| Debt / equity as of 2026-08-10 | 14.95 | 1.31 | RPRX lower |
| Revenue growth (YoY) as of 2026-08-10 | +41.1% | +10.0% | HALO higher |
| Revenue CAGR (3y) SEC XBRL | +28.4% | +2.1% | HALO higher |
| Dividend yield as of 2026-08-10 | n/a | +1.7% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-10 | 0.90 | 0.40 | |
| 1-year return as of 2026-08-07 close | +66.1% | +53.4% | HALO higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.